With ADCs on the rise, drugmakers embrace a new oncology pillar

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

FDA’s Elsa AI is here, and the industry has questions

The agency has provided few details about its AI pilot as it makes moves on its “aggressive timeline” for rollout.  

Biotech CEO confidence hits rock bottom amid policy shifts

A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.

How leading oncology drugmakers set the stage for future advances

Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.

Sanofi to acquire Blueprint for up to $9.5B

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

COVID’s remaining biotech contenders navigate a dwindling market

With policy and funding evolving, companies are being forced to rethink strategies. 

The MAHA agenda won’t include expanding GLP-1 coverage — for now

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.

AbbVie’s ADC win shows how pharma can break through in solid tumors

 An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.

AI expertise is pharma’s next big hiring need — here’s what companies should look for

The widespread hunt for candidates who are equally versed in tech and healthcare is making AI recruiting a challenge. 

With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon

Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

Lilly to buy pain drug developer SiteOne, challenging Vertex

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

What’s next for Trump’s ‘most favored nation’ policy?

HHS set drug price targets last week for pharma manufacturers, while lawmakers proposed new reforms.

Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change

Turnover of the top execs at pharma giants like J&J, AbbVie and Merck in the last few years illustrates the seismic industry shifts that often accompany leadership changes.

Lilly’s former small molecule head makes the leap to a rising biotech in obesity

Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

The placebo effect: How a new FDA rule could pile more strain onto vaccine developers

The proposed plan would require placebo testing for all new vaccines and could mean additional costs and time for R&D.

Regeneron wins bid to buy 23andMe out of bankruptcy

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.

With the third round of Medicare price negotiations on the way, here’s how the policy is shifting

HHS issued guidance for the third cycle, teeing up another 15 drugs to be selected by early next year.  

Tracking a moving target: Drugmakers brace for a looming tariff impact

With policies in flux, companies seek to be proactive and understand their supply chain.

A startup with Theranos ties has another blood test in the works. This time, competition is waiting.

A stealth startup built by the partner of disgraced Theranos founder Elizabeth Holmes is taking a shot at a new blood test — an area where other companies are already making strides.

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.

Trump’s ‘most favored nation’ policy is back. Here’s why it failed the first time.

The controversial plan aims to lower drug prices and will surely trigger another fight with pharma.

Women’s health faces growing headwinds, despite jump in venture investment

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.

With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?

Community oncologists do their best to keep up with new treatments, but with the pace of cancer approvals, drugmakers need to team up with doctors on the front line.

FDA’s future in MAHA hands: How leadership is changing the agency’s trajectory

Who’s in, who’s out and which key positions are still left to be filled in an agency upended.

Lupus R&D has come a long way, and the next breakthroughs could come from cell therapy

But the therapies will need to prove their worth in the clinic over the next few years.